Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Colon cancer
Stage/Subtype:  stage IV colon cancer
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 138 for your search:
Start Over
Direct Peritoneal Resuscitation Plus Conventional Resuscitation
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 12.0262, NCT01882218
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 70 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000692257, NCCTG-N0949, N0949, NCT01279681
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BT-CL-PGG-CRC1031, NCT01309126
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-102, NCT01483027
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1199.52, 2012-000095-42, NCT02149108
Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: Neogenix 0901, NCT01040000
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 07210, NCT01206530
A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: EGEN-001-301, NCT01300858
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162X2109, 2011-002578-21, NCT01449058
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-131, NCT01545141
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IM-T-IMMU-130-02, NCT01605318
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IM-T-IMMU-132-01, NCT01631552
Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00037688, NCT01661972
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CD-ON-MEDI4736-1108, NCT01693562
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLGX818X2103, 2012-002138-35, NCT01719380
Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: PSHCI 11-099, NCT01844076
CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: C32496/1105, NCT01877811
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: NWBio 050012, NCT01882946
Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1369, NA_00085870, NCT01896856
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CMEK162X2116, 2013-001986-18, NCT01927341
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NSABP FC-7, NCT01960023
Genistein in Treatment of Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GCO 13-1697, NCT01985763
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA209-142, 2013-003939-30, NCT02060188
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00461, 13-505, 9525, P30CA006516, U01CA062490, NCT02079740
Start Over